RecruitingPhase 2NCT06577558

Efficacy and Safety of SR1375 in Adult Patients With CAP

A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SR1375 in Hospitalized Adult Patients With Community-acquired Pneumonia

Sponsor

Shanghai SIMR Biotechnology Co., Ltd.

Enrollment

240 participants

Start Date

Sep 10, 2024

Study Type

INTERVENTIONAL

Conditions

Community-acquired Pneumonia

Summary

This is a phase 2 study to evaluate the efficacy and safety of SR1375 in hospitalized adult patients with CAP. Patients will receive SR1375 or placebo for 8 weeks. The study duration for each patient is up to 10 weeks.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo capsule+regular treatments, a drug called SR1375 capsule 0.3mg+regular treatments, and others for people with community-acquired pneumonia. The study is currently recruiting participants at 29 locations. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSR1375 capsule 3mg+regular treatments

SR1375 capsule 3mg QD orally+CAP regular treatments

DRUGSR1375 capsule 1mg+regular treatments

SR1375 capsule 1mg QD orally+CAP regular treatments

DRUGSR1375 capsule 0.3mg+regular treatments

SR1375 capsule 0.3mg QD orally+CAP regular treatments

DRUGPlacebo capsule+regular treatments

Placebo capsule QD orally+CAP regular treatments

Locations(29)

Fuyang People's Hospital

Fuyang, Anhui, China

Peking University Third Hospital

Beijing, Beijing Municipality, China

Zhangzhou Hospital

Zhangzhou, Fujian, China

Gaozhou People's Hospital

Gaozhou, Guangdong, China

The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

The Third Affiliated Hospital of Southern Medical University

Guangzhou, Guangdong, China

Nanfang Hospital

Guangzhou, Guangdong, China

The First Affiliated Hospital of Shantou University Medical College

Shantou, Guangdong, China

Yulin First People's Hospital

Yulin, Guangxi, China

The First Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

Daqing Longnan Hospital

Daqing, Heilongjiang, China

Daqing People's Hospital

Daqing, Heilongjiang, China

Shangqiu People's Hospital

Shangqiu, Henan, China

Henan Provincial People's Hospital

Zhengzhou, Henan, China

Yueyang Central Hospital

Yueyang, Hunan, China

Nanjing First Hospital

Nanjing, Jiangsu, China

Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, China

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Yanbian University Affiliated Hospital

Yanbian, Jilin, China

Dalian Central Hospital

Dalian, Liaoning, China

The Second Hospital of Dalian Medical University

Dalian, Liaoning, China

Weifang Second People's Hospital

Weifang, Shandong, China

Zibo Municipal Hospital

Zibo, Shandong, China

Zhongshan Hospital

Shanghai, Shanghai Municipality, China

Shanghai Tongren Hospital

Shanghai, Shanghai Municipality, China

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

West China Hospital of Sichuan University

Chengdu, Sichuan, China

The First Affiliated Hospital of Chengdu Medical College

Chengdu, Sichuan, China

Lishui Central Hospital

Lishui, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06577558

Related Trials

Epidemiological Study on Community Acquired Pneumonia

NCT021391631 location

Awake Prone Positioning of Patients Suffering Community Acquired Pneumonia Requiring Nasal High Flow Therapy

NCT0696631038 locations

Noninvasive Support Methods for Acute Respiratory Failure of Community-acquired Pneumonia

NCT069968341 location

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

NCT0584871364 locations

Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward

NCT0622928819 locations